Lilly launches Mounjaro in India for treatment of obesity and type 2 diabetes
Adults taking Mounjaro with diet and exercise in a controlled clinical trial lost on average 21.8 kg at the highest dose (15mg) and 15.4 kg at the lowest dose (5mg)
Adults taking Mounjaro with diet and exercise in a controlled clinical trial lost on average 21.8 kg at the highest dose (15mg) and 15.4 kg at the lowest dose (5mg)
Company expects to begin building four more domestic manufacturing sites this year and add 13,000 high-wage manufacturing and construction jobs in America
Lilly plans to hire approximately more than 1,000 new highly-skilled team members
The huminsulin range of products is indicated for the treatment of type 1 and type 2 diabetes mellitus to improve blood sugar control in both adults and childre
The Lilly Medicine Foundry is set to drive innovation in drug production and make medicines for clinical trials
Lilly will license certain baricitinib manufacturing know-how to enable EVA Pharma to manufacture and supply treatment for various immunological diseases
This partnership aims to accelerate research and development into innovative treatments and, if successful, will generate milestones and royalties
Acquisition to expand Lilly's immunology pipeline with oral integrin therapies
SYNERGY-NASH results were presented at the European Association for the Study of the Liver Congress 2024 and simultaneously published in The New England Journal of Medicine
Ashkenazi will continue to serve at full capacity in her role and as a member of Lilly's Executive Committee through July 2024
Subscribe To Our Newsletter & Stay Updated